ERBB2 and paramyotonia congenita of Von Eulenburg: Some studies have suggested that neoadjuvant chemotherapy or a combination of anti‐HER2 therapies can be employed for the treatment of triple‐negative PMC and HER‐2 overexpression PMC.37